|
|
Article: Dynogen enters into irritable bowel syndrome agreement with Mitsubishi.(Dynogen Pharmaceuticals Inc., Mitsubishi Pharma Corp.)
- Article from:
- BIOTECH Patent News
- Article date:
- December 1, 2003
CopyrightCOPYRIGHT 2003 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Demonstrating rapid progress in building its clinical pipeline, Dynogen Pharmaceuticals, Inc. (Boston, MA) has entered into a Technology Transfer and License agreement with Mitsubishi Pharma Corporation involving a neurological compound that Dynogen will develop for the treatment of irritable bowel syndrome (IBS). The compound, DDP-225 (formerly MCI-225), is one of two Dynogen drug candidates expected to enter Phase II clinical trials during 2004.
The agreement provides Dynogen with rights to all clinical trial data and other information useful for the research, development and manufacturing of the compound, as well as a supply of drug material adequate to ...
Related newspaper, magazine, and journal articles:
|
|
Article: Apex Bioventures and Dynogen Pharmaceuticals ...
Business Wire;
February 6, 2008 ;
700+ words
... ... acquisition company with healthcare industry expertise, and Dynogen Pharmaceuticals, Inc., a privately owned clinical stage biopharmaceutical ... of Apex Bioventures, which will change its name to Dynogen Pharmaceuticals, Inc. * The Board of Directors of the combined company ...
|
|